Baseline characteristics.

TB, tuberculosis; ART, antiretroviral therapy; IQR, interquartile range; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; AZT, zidovudine; EFV, efavirenz. aData on CD4 count and CD4 percentage were not available for 282 patients (16 with incident TB); CD4 counts and percentages were closest recorded values to the baseline start date, maximum 6 months pre and 15 days post ART initiation. Data on WHO stage were not available for 25 patients. bOther first line triple ART regimens.TB（tuberculosis，结核病）；ART（antiretroviral therapy，抗反转录病毒治疗）；IQR（interquartile range，四分位距）；d4T（stavudine，司他夫定）；3TC（lamivudine，拉米夫定）；NVP（nevirapine，奈韦拉平）；AZT（zidovudine，齐多夫定）；EFV（efavirenz，依非韦伦）。注a：282例患者（其中16例为新发结核病病例）未提供CD4细胞计数及CD4百分比相关数据；所记录的CD4细胞计数与百分比为距离抗反转录病毒治疗（ART）起始基线日期最近的记录值，采集时间范围为治疗前6个月至治疗后15天。25例患者未提供世界卫生组织（WHO）疾病分期相关数据。注b：其他一线三联抗反转录病毒治疗方案。